

Title (en)  
FUSION PROTEIN FROM ANTIBODY CYTOKINE-CYTOKINE INHIBITOR (SELECTOKINE) FOR USE AS TARGET-SPECIFIC PRODRUG

Title (de)  
FUSIONSPROTEIN AUS ANTIKÖRPER-ZYTOKIN-ZYTOKIN INHIBITOR (SELEKTOKIN) ALS ZIELSPEZIFISCHES PRODRUG

Title (fr)  
PROTEINE DE FUSION CONSTITUEE D'UN INHIBITEUR D'ANTICORPS-CYTOKINE-CYTOKINE (SELECTOKINE) SERVANT DE PROMEDICAMENT SPECIFIQUE A LA CIBLE

Publication  
**EP 1317556 A1 20030611 (DE)**

Application  
**EP 01974261 A 20010917**

Priority  
• DE 10045592 A 20000915  
• EP 0110730 W 20010917

Abstract (en)  
[origin: WO0222833A1] Die vorliegende Erfindung betrifft ein Polypeptid mit vorzugsweise antitumoralen und/oder immunmodulierenden Zytokineigenschaften, welches durch Prozessierung <i>in vivo</i> aktivierbar ist, umfassend eine zentrale Region mit spezifischer biologischer Aktivität, an dessen C-terminalen Ende sich eine Region mit einer Prozessierungseinheit und einer Inhibitor-domäne befindet, während sich am N-terminalen Ende eine Region befindet, die ein Makromolekül auf einer Zelloberfläche oder eine Komponente der extrazellulären Matrix selektiv erkennt.  
[origin: WO0222833A1] The invention relates to a polypeptide having preferably antitumoral and/or immunomodulating cytokine properties which can be activated by processing it <i>in vivo</i>. Said polypeptide comprises a central region that has a specific biological activity. At the C-terminus, said region comprises a region with a processing unit and an inhibitor domain while at its N-terminus it comprises a region that selectively recognizes a macromolecule on a cell surface or a component of the extracellular matrix.

IPC 1-7  
**C12N 15/62**; C07K 19/00; C12N 15/63; C12N 1/21; C12N 5/10; A61K 47/48

IPC 8 full level  
**A61K 38/00** (2006.01); **A61K 47/48** (2006.01); **A61K 48/00** (2006.01); **A61P 35/00** (2006.01); **C07K 14/525** (2006.01); **C07K 14/715** (2006.01); **C12N 15/09** (2006.01); **C07K 16/18** (2006.01); **C07K 16/40** (2006.01); **C07K 16/46** (2006.01); **C07K 19/00** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **C12P 21/02** (2006.01)

CPC (source: EP KR US)  
**A61K 47/6849** (2017.08 - EP US); **A61P 35/00** (2018.01 - EP); **C07K 14/525** (2013.01 - EP US); **C07K 14/7151** (2013.01 - EP US); **C07K 16/40** (2013.01 - EP US); **C07K 19/00** (2013.01 - KR); **C07K 2317/24** (2013.01 - EP US); **C07K 2317/622** (2013.01 - EP US); **C07K 2319/00** (2013.01 - EP US)

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0222833 A1 20020321**; AU 9381901 A 20020326; BG 107613 A 20031231; BR 0113928 A 20030722; CA 2422759 A1 20030317; CN 1214115 C 20050810; CN 1458977 A 20031126; DE 10045592 A1 20020328; EE 200300100 A 20050215; EP 1317556 A1 20030611; HR P20030192 A2 20051031; HU P0301693 A2 20030828; HU P0301693 A3 20051128; IL 154185 A0 20030731; JP 2004508828 A 20040325; KR 20030048041 A 20030618; MX PA03002229 A 20050620; NO 20031185 D0 20030314; NO 20031185 L 20030505; PL 360540 A1 20040906; RU 2003106429 A 20040827; SK 2812003 A3 20031104; US 2004053829 A1 20040318; YU 18903 A 20060525; ZA 200302008 B 20040625

DOCDB simple family (application)  
**EP 0110730 W 20010917**; AU 9381901 A 20010917; BG 10761303 A 20030306; BR 0113928 A 20010917; CA 2422759 A 20010917; CN 01815764 A 20010917; DE 10045592 A 20000915; EE P200300100 A 20010917; EP 01974261 A 20010917; HR P20030192 A 20030314; HU P0301693 A 20010917; IL 15418501 A 20010917; JP 2002527275 A 20010917; KR 20037003738 A 20030314; MX PA03002229 A 20010917; NO 20031185 A 20030314; PL 36054001 A 20010917; RU 2003106429 A 20010917; SK 2812003 A 20010917; US 38043803 A 20030411; YU P18903 A 20010917; ZA 200302008 A 20030312